Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Franklin Resources Inc.

Franklin Resources Inc. increased its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 171.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 278,295 shares of the medical equipment provider's stock after purchasing an additional 175,855 shares during the period. Franklin Resources Inc. owned 0.12% of Hologic worth $22,714,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Hologic by 11.3% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 4,804 shares of the medical equipment provider's stock worth $357,000 after purchasing an additional 487 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Hologic by 20.4% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 251,869 shares of the medical equipment provider's stock worth $18,701,000 after acquiring an additional 42,661 shares during the last quarter. HB Wealth Management LLC raised its holdings in shares of Hologic by 6.1% during the 2nd quarter. HB Wealth Management LLC now owns 5,795 shares of the medical equipment provider's stock worth $430,000 after acquiring an additional 332 shares in the last quarter. Banco Santander S.A. boosted its position in shares of Hologic by 5.8% during the 2nd quarter. Banco Santander S.A. now owns 4,670 shares of the medical equipment provider's stock valued at $347,000 after acquiring an additional 258 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Hologic by 4.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 353,782 shares of the medical equipment provider's stock valued at $26,268,000 after purchasing an additional 16,387 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Up 1.3 %

Shares of Hologic stock traded up $0.89 on Friday, reaching $71.65. The stock had a trading volume of 8,560,791 shares, compared to its average volume of 1,672,050. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $16.26 billion, a P/E ratio of 21.52, a P/E/G ratio of 2.38 and a beta of 0.96. The company has a 50 day moving average price of $78.65 and a 200 day moving average price of $78.52. Hologic, Inc. has a 1 year low of $70.36 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business's quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.89 earnings per share. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.75% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on HOLX shares. UBS Group increased their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Citigroup cut Hologic from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. BNP Paribas raised Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 price target on shares of Hologic in a report on Thursday. Finally, Jefferies Financial Group assumed coverage on Hologic in a research report on Tuesday, December 10th. They issued a "hold" rating and a $85.00 price objective on the stock. Six analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $89.50.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.